KYNB, US31572Q8814

Kyntra Bio stock pivots after Q3 results, ends oncology programs

Published on 11/19/2026 at 03:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Kyntra Bio stock faces a pipeline reset after third-quarter results and the end of two oncology programs. Roxadustat now leads its strategy.

Rare disease focus takes shape

  • Kyntra Bio plans a pivotal roxadustat Phase 3 trial in the first quarter of 2027, subject to partnership or external financing.
  • The company expects the discontinued oncology programs to reduce operating expenses by more than 20 million US dollars across 2027 and 2028.
  • A royalty financing amendment reduced the maximum aggregate payment obligation by 60 million US dollars.
KYNB, US31572Q8814, Illustration mit AI erstellt.

Kyntra Bio reported its third-quarter 2026 results on November 16 and said it would discontinue development of the FG-3246 and FG-3180 programs after a pre-specified Phase 2 interim analysis failed to support continued development. The company is redirecting resources toward roxadustat and a planned pivotal Phase 3 study in lower-risk myelodysplastic syndromes with high transfusion burden.

Kyntra Bio reported third-quarter revenue of 1.8 million US dollars, compared with 1.1 million US dollars a year earlier. Net income from continuing operations was 0.2 million US dollars, versus a 13.1 million US dollar loss in the year-earlier quarter. The result included a 14.0 million US dollar gain on debt restructuring.

Roxadustat becomes central program

The company plans to begin the roxadustat Phase 3 trial in the first quarter of 2027, but the timetable depends on a strategic partnership or an external capital raise. Kyntra Bio said the termination of FG-3246 and FG-3180 should reduce operating expenses by more than 20 million US dollars in 2027 and 2028.

Kyntra Bio also completed a restructuring of its royalty financing agreement. The maximum aggregate payment obligation fell from 125 million US dollars to 65 million US dollars, while remaining royalty-backed payments are capped at 15 million US dollars. Cash, cash equivalents, investments and accounts receivable totaled 44.1 million US dollars at September 30, and management expects those resources to fund operating plans into 2028.

Biopharmaceutical pipeline and market position

Kyntra Bio is a US biopharmaceutical company focused on developing therapies for rare diseases and oncology. Its lead program is roxadustat, an oral HIF-PH inhibitor used in anemia treatment, with planned development in lower-risk myelodysplastic syndromes. The company is headquartered in San Francisco and is shifting toward a rare-disease-focused operating model.

Kyntra Bio at a glance

  • Company: Kyntra Bio, Inc.
  • ISIN: US31572Q8814
  • Ticker: KYNB
  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters: San Francisco, United States

Kyntra Bio operates within the US market environment tracked by the S&P 500.

Find More news and analyses on Kyntra Bio stock.

Disclaimer...
en | US31572Q8814 | KYNB | boerse | 70533438 | bgmi